Outcome of Board Meeting held on May 20, 2026 as per SEBI (LODR) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.8 pts more than Nifty Microcap 250 and 4.3 pts more than its Retailing peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
MedPlus Health Services reported strong FY2026 results with consolidated revenue growing 12.3% to Rs. 68,924.66 million (from Rs. 61,360.53 million). Profit after tax surged 46.2% to Rs. 2,196.06 million from Rs. 1,502.33 million in the prior year, driven by growth in retail and diagnostic segments. The company allotted 82,419 equity shares under ESOP 2021, increasing paid-up capital to Rs. 240.11 million. Board changes include completion of tenure for two Independent Directors (Madhavan Ganesan and Murali Sivaraman from June 10, 2026), appointment of two new Independent Directors (Ajit Pandurang Rangnekar and Mohankrishna Reddy Arvabumi), and re-appointment of Managing Director Gangadi Madhukar Reddy for five years from August 2026. The Company Secretary resigned, and cost auditor M P R & Associates was re-appointed for FY2027. The statutory auditor B S R and Co issued an unmodified (clean) opinion on both standalone and consolidated financial statements.
Strong profit growth of 46% demonstrates operational efficiency improvement. Board renewal with new independent directors brings fresh perspective. The resignation of Company Secretary may cause short-term compliance attention. Clean audit opinion with no going concern issues is positive for investor confidence.